Suppr超能文献

自闭症谱系障碍患者采用雷美替胺与苏沃雷生联合治疗非 24 小时睡眠-觉醒障碍取得良好效果。

Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder.

机构信息

Department of Neuropsychiatry, Faculty of Medicine, Tottori University, Yonago, Japan.

出版信息

Neuropsychopharmacol Rep. 2020 Dec;40(4):383-387. doi: 10.1002/npr2.12142. Epub 2020 Sep 29.

Abstract

INTRODUCTION

Non-24-hour sleep-wake disorder (N24SWD) is often observed in the visually impaired and those who isolate indoors. Melatonin receptor agonists may be used for treatment, but there is currently no evidence that they are effective in patients without visual impairment.

CASE

We report a case of a 23-year-old woman who withdrew from her social life owing to autism spectrum disorder and experienced an unusual sleep rhythm. She presented with N24SWD. The N24SWD cycle averaged 25.6 days but was extended to 42 days using ramelteon. However, this was not enough. We prescribed the addition of suvorexant and the sleep cycle returned to normal.

CONCLUSION

N24SWD is a disease that seriously impairs social life and productivity. We propose a possible treatment strategy for N24SWD using ramelteon and suvorexant.

摘要

简介

非 24 小时睡眠-觉醒障碍(N24SWD)常发生于视障人群和长期室内隔离人群。褪黑素受体激动剂可能对此有治疗效果,但目前尚无证据表明其对视障人群以外的患者有效。

病例

我们报告了一例 23 岁女性病例,该患者因自闭症谱系障碍而退出社交生活,出现异常睡眠节律。患者表现为 N24SWD。N24SWD 周期平均为 25.6 天,但使用雷美替胺后延长至 42 天。然而,这还不够。我们建议加用苏沃雷生,此后睡眠周期恢复正常。

结论

N24SWD 是一种严重影响社交和生产力的疾病。我们提出了一种使用雷美替胺和苏沃雷生治疗 N24SWD 的可能策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19bf/7722683/073e36dfd180/NPR2-40-383-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验